Table 5.

Association of clinicopathologic features with overall survival

	n	No. events	Median OS	5-years OS	p-value^a
Age	47	11	--	--	0.3523
Primary Tumor Size	47	11	--	--	0.5842
Gender
Female	17	3	12.17	1	0.0209
Male	30	8	10.24	0.78
Histology
Gastrointestinal Stromal Tumor	13	3	10.24	0.92	0.1806
Leiomyosarcoma	3	1	12.17	1
Liposarcoma	5	2	7.52	1
Synovial	3	0	NR	1
Chondrosarcoma	3	1	5.96	1
Other	20	4	NR	0.61
Original Location
Trunk	5	0	NR	NR	0.2957
Abdomen/Pelvis/Retroperitoneum	29	8	10.24	0.91
Head & Neck	6	3	2.78	0.5
Extremities	7	0	NR	1
Grade
Low	5	0	NR	1	0.4201
Intermediate/High	36	10	10.24	0.85
Depth
Superficial	3	1	12.17	1	0.0534
Deep	42	10	10.24	0.84
Margins
Negative	34	6	11.33	0.9	0.3846
Positive	13	5	8.13	0.74
Tumor PDL1
Neg	43	10	10.24	0.87	0.8678
Pos	4	1	NR	0.75
Lymphocyte PDL1
Neg	32	9	10.24	0.88	0.8764
Pos	14	2	NR	0.76
Macrophage PDL1
Neg	14	3	11.33	0.92	0.3326
Pos	28	7	10.24	0.79
Tumor PD1
Neg	37	8	11.33	0.85	0.1202
Pos	10	3	8.13	0.71
Macrophage Infiltration
No	3	1	6.91	1	0.6489
Yes	44	10	11.33	0.85
Lymphocyte Infiltration
Yes	47	11	10.24	0.86	--
CD3
0–5%	27	5	11.33	0.95	0.0496
>5%	20	6	8.13	0.72
CD4
0–5%	43	8	11.33	0.91	0.0459
>5%	4	3	6.51	0.5
CD8
0–5%	38	8	11.33	0.89	0.091
>5%	9	3	10.24	0.71
FOXP3
0%	16	4	11.33	0.92	0.2598
1–5%	31	7	10.24	0.83
CD8/FOXP3 Ratio
<= 1	12	2	6.91	0.9	0.707
>1	12	4	10.24	0.79

Abbreviations: OS overall survival, NR not reached

: p <0.05 set as significant